Condition: FL Lymphoma · Epithelioid Sarcoma · Peripheral T Cell Lymphoma · Sponsor: Haihe Biopharma Co., Ltd.
This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.
This description comes directly from the study's public registry record.
Haiyue Chen · +86 21 20568888 · haiyue.chen@haihepharma.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Phoenix, Arizona, United States | Completed |
| Mayo Clinic | Jacksonville, Florida, United States | Completed |
| Mayo Clinic | Rochester, Minnesota, United States | Completed |
| NEXT Oncology | San Antonio, Texas, United States | Completed |
| The First Affiliated Hospital of Anhui Medical University | Hefei, Anhui, China | Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Jishuitan Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Sun Yat-Sen University Cancer Hospital | Guangzhou, Guangdong, China | Recruiting |
| Affiliated Tumor Hospital of Guangxi Medical University | Nanning, Guangxi, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04390737